Global drugmakers continue to defend rights for their original drugs in Russia

Global drugmakers continue to defend the rights for their original drugs in Russia by participating in legal disputes with local generics’ producers, The Pharma Letter’s local correspondent reports.

One such company is Germany’s Bayer (BAYN: DE), which in March of the current year filled a lawsuit with the Moscow Arbitration Court against the Russian Medisorb company, asking it to cancel the state registration of rivaroxaban with the active ingredient of Xarelto, which is protected by Bayer’s patent until December 4, 2024, and to oblige the Russian company to stop the storage and production of a similar drug.

However, according to some Russian media reports, several days ago the parties, entered into a settlement agreement under the terms of which Medisorb voluntarily recognized the exclusive right of the German drugmaker to rivaroxaban and provided guarantees not to violate it until the expiration of the patent. A spokesman for Medisorb declined to comment.